Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb’s HIV study meets primary end point
In this study, 78% of the 440 patients in the Reyataz /r arm met the primary endpoint of achieving undetectable viral load (defined as HIV-1 RNA less than
In this study, 78% of the 440 patients in the Reyataz /r arm met the primary endpoint of achieving undetectable viral load (defined as HIV-1 RNA less than
Initial in vitro testing conducted by the Provincial Laboratory for Public Health (ProvLab) in Alberta, Canada, showed that Upstream’s potential drug candidates demonstrated anti-malarial activity in the nanomolar
The goal of these studies, which utilized two different dosing regimens, was to further test the ability of Senesco’s Factor 5A technology to induce apoptosis in tumors. Additionally,
The Neuracept trial was a double blind, placebo-controlled study of NP-1 in 215 diabetic peripheral neuropathy (DPN) patients who completed the trial. The data demonstrated that the primary
The final purchase price is subject to adjustment based on the closing net cash balance and working capital of the business and is expected to generate net proceeds,
The US Phase IIa ‘PLUS’ trial will evaluate up to 56 patients with chronic hepatitis C. The PLUS trial will evaluate safety, tolerability, pharmacokinetics and viral kinetics of
Under the agreement, Idera exclusively licensed the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. With the grant of HSR clearance, the
The Center for Devices and Radiological Health (CDRH) received Female Health Company’s (FHC) PMA on January 8, 2008.
The company will use the proceeds to complete the clinical development of its lead product, CARDIOsphere (PB127). Parag Saxena, co-founder and managing partner of Vedanta Capital, and Larry
As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity. Shipment of